Overview

Pediatric Long-Term Follow-up and Rollover Study

Status:
Recruiting
Trial end date:
2026-05-29
Target enrollment:
Participant gender:
Summary
A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Dabrafenib
Trametinib